Patients will be included in the study based on the following criteria:

          -  Signed informed consent

          -  Histologically confirmed, palpable, regional lymph node metastatic melanoma ≥ 1.5cm
             (stage IIIB-C; N1b-3) either at initial presentation or at regional lymph node
             recurrence considered surgically resectable at baseline by the treating medical
             oncologist and surgical oncologist

          -  Patients with intransit or satellite metastases with lymph node involvement are
             allowed if considered surgically resectable at baseline

          -  Measurable disease per RECIST 1.1

          -  Melanoma must be documented to contain a BRAFV600 mutation by a CLIA approved
             laboratory

          -  No evidence of distant metastasis

          -  Age ≥ 18 years

          -  ECOG performance status ≤1

          -  Adequate bone marrow function as indicated by the following:

               -  ANC greater than 1500/µL

               -  Platelets ≥ 100,000/µL

               -  Hemoglobin greater than 9 g/dL

          -  Adequate renal function, as indicated by creatinine ≤1.5 x the upper limit of normal
             (ULN)

          -  Adequate liver function, as indicated by bilirubin ≤1.5 x ULN

          -  AST or ALT less than 3 x ULN (patients with documented liver metastases: AST and/or
             ALT ≤5 x ULN)

          -  Able to swallow pills

          -  Negative serum pregnancy test within 7 days prior to commencement of dosing in
             premenopausal women. Women of non-childbearing potential may be included without serum
             pregnancy test if they are either surgically sterile or have been postmenopausal for ≥
             1 year.

          -  Fertile men and women must use an effective method of contraception during treatment
             and for at least 6 months after completion of treatment as directed by their
             physician. Effective methods of contraception are defined as those which result in a
             low failure rate (i.e., less than 1% per year) when used consistently and correctly
             (for example implants, injectables, combined oral contraception or intra-uterine
             devices). At the discretion of the Investigator, acceptable methods of contraception
             may include total abstinence in cases where the lifestyle of the patient ensures
             compliance. (Periodic abstinence [e.g., calendar, ovulation, symptothermal,
             post-ovulation methods] and withdrawal are not acceptable methods of contraception.)

          -  Willing and able to undergo biopsy for research purposes

          -  Willing and able to sign informed consent

        Exclusion Criteria:

          -  Had prior radiotherapy at lymph node basin

          -  Prior treatment with BRAF inhibitor or MEK inhibitor

          -  Active infection

          -  Pregnant, lactating or breast feeding women

          -  Concomitant malignancies or previous malignancies within the last 5 years, with the
             exception of adequately treated basal or squamous cell carcinoma of the skin or
             carcinoma in situ of the cervix.

          -  History of malabsorption or other condition that would interfere with absorption of
             vemurafenib or cobimetinib

          -  Any underlying medical or psychiatric condition, which in the opinion of the
             Investigator will make the administration of vemurafenib and cobimetinib hazardous

          -  Unwillingness or inability to comply with study and follow-up procedures.

          -  The following foods/supplements are prohibited at least 7 days prior to initiation of
             and during study treatment:

               -  St. John's wort or hyperforin (potent cytochrome P450 CYP3A4 enzyme inducer)

               -  Grapefruit juice (potent cytochrome P450 CYP3A4 enzyme inhibitor)